Clinigence Holdings (NUTX) AI Stock Analysis

• Market Cap: $1.05B
• Dividend Yield: N/A
• Average Volume (3M): 137.83K
• Price to Earnings (P/E): 7.7
• Beta (1Y): 2.18
• Revenue Growth: 236.03%
• EPS Growth: N/A
• Country: US
• Employees: 800
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 7,071,916
• 10 Day Avg. Volume: 139,051
• 30 Day Avg. Volume: 137,834
• PEG Ratio: -0.02
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.34
• P/FCF Ratio: 7.75
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 1.10
• Enterprise Value/Gross Profit: 2.00
• Enterprise Value/Ebitda: 2.98
• 1Y Price Target: $265.00
• Price Target Upside: 43.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 80 Outperform
• Price Target: $171.00 ▼(-7.12% Downside)

The score is led by strong financial performance (rapid revenue and free-cash-flow growth with solid margins) and reinforced by a clear upward technical trend (price above all key moving averages with positive MACD). Valuation is supportive given the low P/E, while historical financial volatility and past leverage risk keep the score from being higher.

Positive Factors

Revenue Growth & Margins

Sustained ~24% TTM revenue growth with healthy gross and net margins indicates the underlying software and services model scales efficiently. Durable margins support reinvestment in product development and sales, reinforcing long-term competitive positioning and margin resilience.

Free Cash Flow Generation

Very strong FCF growth and near-1:1 FCF-to-net-income conversion demonstrate high cash conversion from operations. This persistent cash generation provides durable funding for R&D, integration of customers, selective M&A, and debt reduction without relying on external financing.

Improved Leverage & High ROE

Reduced leverage to a 0.75 D/E and very strong ROE reflect improved balance sheet health and efficient use of equity capital. Lower structural leverage increases financial flexibility to invest in growth initiatives while maintaining resilience to industry shocks over the medium term.

Negative Factors

Historical Financial Volatility

Past episodes of volatility and previously elevated leverage highlight a structural risk: earnings and cash flows have shown instability. That history suggests management must consistently execute on margins and balance-sheet repair to prevent recurrence and protect long-term financial flexibility.

Profitability Fluctuations

Documented swings in profitability reduce predictability of margins and cash flow, complicating long-term planning for R&D and sales investments. Persistent profit volatility can impair sustained margin expansion and makes forecasting revenue-to-capex trade-offs more challenging for management.

High Market Sensitivity (Beta)

A high beta indicates earnings and equity value are structurally more sensitive to market and macro swings, which can translate into greater variability in access to capital and financing costs. This raises the company’s exposure to cyclical pressures on healthcare IT spending.

Clinigence Holdings Business Overview & Revenue Model

Company Description

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

How the Company Makes Money

Clinigence Holdings generates revenue through multiple streams, primarily by offering subscription-based services for its software platforms that help healthcare providers manage patient data and improve care coordination. The company also earns revenue from consulting services that assist healthcare organizations in implementing its technologies effectively. Additionally, partnerships with healthcare institutions and payers enhance its market reach and diversify income sources. These partnerships often lead to joint initiatives that can result in shared revenue from improved patient care outcomes and operational efficiencies.

Clinigence Holdings Financial Statement Overview

Summary

Strong operating profile driven by 23.86% TTM revenue growth, healthy margins (gross 55.01%, net 11.63%) and robust cash conversion (FCF to net income 99.74%) with 71.03% TTM FCF growth. Balance sheet is improved with lower leverage (debt-to-equity 0.75) and strong ROE (40.80%), but historical volatility and prior higher leverage temper the score.

Income Statement

Clinigence Holdings has demonstrated strong revenue growth with a 23.86% increase in TTM, supported by solid gross and net profit margins of 55.01% and 11.63% respectively. The EBIT and EBITDA margins are also robust at 34.79% and 36.89%, indicating efficient operational management. However, the company has experienced fluctuations in profitability in previous years, which could pose a risk if not managed.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.75 in TTM, showing a reduction in leverage compared to previous years. The return on equity is strong at 40.80%, reflecting effective use of equity capital. However, the equity ratio is not explicitly provided, and historical high leverage ratios suggest potential financial risk if not monitored.

Cash Flow

Clinigence Holdings has shown impressive free cash flow growth of 71.03% in TTM, with a high free cash flow to net income ratio of 99.74%, indicating strong cash generation relative to earnings. The operating cash flow to net income ratio is also healthy at 95.87%. Despite these strengths, the company has faced cash flow challenges in the past, which should be considered.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	981.20M	479.95M	247.65M	219.29M	331.53M	274.03M
Gross Profit	539.77M	196.26M	34.77M	15.42M	179.28M	157.61M
EBITDA	361.94M	148.65M	-14.58M	-394.03M	183.45M	158.07M
Net Income	114.07M	52.18M	-45.79M	-424.78M	132.59M	105.97M
Balance Sheet
Total Assets	964.52M	655.32M	398.25M	431.75M	394.65M	308.55M
Cash, Cash Equivalents and Short-Term Investments	166.05M	43.58M	22.00M	34.26M	36.12M	25.51M
Total Debt	358.60M	340.30M	275.76M	267.20M	178.55M	150.12M
Total Liabilities	526.49M	453.43M	319.14M	311.42M	203.07M	161.19M
Stockholders Equity	317.17M	146.34M	61.45M	95.86M	114.65M	85.81M
Cash Flow
Free Cash Flow	224.03M	20.85M	-8.24M	35.97M	136.51M	25.48M
Operating Cash Flow	224.79M	23.15M	1.26M	50.61M	173.43M	86.67M
Investing Cash Flow	-565.25K	-2.67M	-11.24M	-4.34M	-36.98M	-61.19M
Financing Cash Flow	-55.14M	1.09M	-2.27M	-48.13M	-125.85M	-7.97M

Clinigence Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 184.11
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Neutral. The current price of 184.11 is above the 20-day moving average (MA) of 162.47, above the 50-day MA of 157.84, and above the 200-day MA of 125.46, indicating a neutral trend. The MACD of -3.41 indicates Positive momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of 26.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NUTX.

Clinigence Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUTX	80 Outperform	$1.05B	7.72	63.86%	―	236.03%	―
HSTM	69 Neutral	$661.30M	32.67	5.87%	0.52%	3.68%	5.62%
TXG	60 Neutral	$2.56B	-32.33	-10.12%	―	1.92%	59.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HCAT	50 Neutral	$152.07M	-1.36	-31.33%	―	4.64%	-17.17%
DH	49 Neutral	$328.63M	-1.38	-47.69%	―	-5.30%	46.01%
EVH	48 Neutral	$358.24M	-2.05	-13.63%	―	-16.65%	-71.92%

Clinigence Holdings Corporate Events

Clinigence Holdings Files Auditors’ Consent for Nutex

Clinigence Holdings has filed an auditors’ consent related to Nutex Health Inc.’s consolidated financial statements for the years ending December 31, 2023. This filing, made on November 18, 2025, incorporates these financial statements into previously filed registration statements, potentially impacting stakeholders’ understanding of the company’s financial health.

The most recent analyst rating on (NUTX) stock is a Buy with a $164.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.